Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Edgewise Therapeutics (Nasdaq: EWTX), a biopharmaceutical company focused on muscle diseases, has granted inducement stock options to 2 new non-executive employees.

Rhea-AI Summary

Edgewise Therapeutics (Nasdaq: EWTX), a biopharmaceutical company focused on muscle diseases, has granted inducement stock options to 2 new non-executive employees. The options allow the purchase of 16,500 shares at an exercise price of $14.35 per share, matching the closing price on the grant date of August 29, 2025.

The options, granted under the company's 2024 Inducement Equity Incentive Plan, will vest over four years, with 25% vesting after one year and the remaining vesting monthly at a rate of 1/48th, contingent on continued employment. These grants comply with Nasdaq Listing Rule 5635(c)(4) as employment inducements.

Argus Sep 4 session

-0.10% close to close Open Argus

Details

News Market Reaction – EWTX

On Sep 4, the first trading day after this news, EWTX closed 0.10% below the previous close.

Data tracked by StockTitan Argus for the Sep 4 session.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOULDER, Colo., Sept. 3, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on August 29, 2025, Edgewise granted inducement stock options to purchase a total of 16,500 shares of Edgewise's common stock to 2 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan"). 

Each inducement stock option has an exercise price of $14.35 per share, which is equal to the closing price of a share of Edgewise common stock on the grant date, and shall vest as follows: 25% of the shares subject to such inducement stock option shall vest on the one year anniversary of the start date of each employee, and an additional one forty-eighth (1/48th) of the shares subject to such inducement stock option shall vest monthly thereafter, subject to the employee's continued service.

Each inducement award is subject to the terms of the Inducement Plan and related forms of agreements, and were granted as inducements material to these employees to enter into employment with Edgewise in accordance with Nasdaq Listing Rule 5635(c)(4). 

About Edgewise Therapeutics 

Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, currently in Phase 2 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn, X , Facebook and Instagram.

View original content to download multimedia:https://www.prnewswire.com/news-releases/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-302545849.html

SOURCE Edgewise Therapeutics

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock options did Edgewise Therapeutics (EWTX) grant to new employees in August 2025?

Edgewise granted inducement stock options to purchase 16,500 shares at $14.35 per share to 2 new non-executive employees.

What is the vesting schedule for EWTX's August 2025 inducement stock options?

The options vest 25% after one year, with the remaining vesting monthly at 1/48th of the shares, subject to continued employment.

What is the purpose of Edgewise Therapeutics' 2024 Inducement Equity Incentive Plan?

The plan allows Edgewise to grant stock options as employment inducements to attract new employees, in compliance with Nasdaq Listing Rule 5635(c)(4).

How many new employees received stock options from EWTX in August 2025?

Two new non-executive employees received inducement stock options from Edgewise Therapeutics.